Scientific Advisory Board

  • kapil


  • Kapil Dhingra, MD

    Kapil Dhingra, MBBS, has a broad range of experience in strategic oncology research and development. Dr. Dhingra is Managing Member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies and investors. He serves on the Board of Directors and/or Scientific/Clinical Advisory Boards of a number of companies and non-profit organizations. Present and past BoD involvements include Exosome Diagnostics (US, Chairman), Advanced Accelerator Applications (France), Autolus (UK), Median Technologies (France), Replimune Inc (US),Five Prime Inc. (US), Algeta (acquired by Bayer), YM Biosciences (acquired by Gilead), Micromet (acquired by Amgen),Biovex (acquired by Amgen),and, Epitherapeutics (acquired by Gilead), among others.

    From 1999 to 2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc., including as Vice President, Head, Oncology Disease Biology Leadership team; and Head, Oncology Clinical Development. In this capacity, he played a leading role in building the largest oncology franchise in the pharmaceutical industry. He joined Roche from Eli Lilly, where he worked as Senior Clinical Research Physician. Before joining industry and during his tenures at both Eli Lilly and Hoffmann-La Roche, Dr. Dhingra maintained an active academic career first as an Assistant Professor at M.D. Anderson Cancer Center, then as a Clinical Associate Professor at Indiana University School of Medicine and, most recently, as a Clinical Affiliate at Memorial Sloan Kettering Cancer Center. He also serves on the NeXT panel of the National Cancer Institute (NCI).

  • klackey

  • Karen Lackey

    Karen Lackey is currently the Director, Arizona Center for Drug Discovery (ACDD) at the University of Arizona that serves as an organizational hub for supporting academic-based drug discovery throughout the state. Lackey is also an entrepreneur in early stage biotechnology, contributing to start-ups in platform technologies (e.g. Pyramid Biosciences, Neuroene Therapeutics, and Centaur Biosciences). Prior roles included Vice President and Head of Medicinal Chemistry at Hoffmann-La Roche (USA) and Global Vice President of Discovery Chemistry in the Molecular Discovery Research Division for GlaxoSmithKline. Most importantly, she played an active role in the discovery of the dual erbB2/EGFR tyrosine kinase inhibitor, lapatinib, currently marketed as Tykerb®. Karen has over 100 publications and patents, principally covering oncology, inflammation, kinase inhibition, gene family molecular design and cellular signaling.

  • fbarany

  • Francis Barany, Ph.D.

    Francis Barany is a Professor of Microbiology and Immunology at Weill Cornell Medicine. Barany is best known for inventing the ligase chain reaction (LCR), ligase detection reaction (LDR), and Universal DNA arrays, which are the foundation of commercial tests to diagnose genetic diseases, detect infectious pathogens, identify cancer mutations, and identify diseases using DNA microarrays and targeted Next-Gen sequencing. He received a Helen Hay Whitney Fellow (1982-1985), Hirschl/Monique Weill-Caulier Career Scientist Award (1992-1997), Mayent/Rothschild Visiting Professor, Institut Curie (2000), Medical Diagnostics Research leader, Scientific American 50 (2004), Ezra Innovation Award, Cornell University (2011), International Federation of Clinical Chemistry Award for Significant Contributions in Molecular Diagnostics (2014), and National Academy of Inventors Fellow (2016). Barany holds 58 U.S. and 105 international patents that are widely used by molecular diagnostic and sequencing companies. Barany founded Coferon Inc. and Acuamark Diagnostics Inc.; the later for detection of early cancer directly from blood. He has published over 120 peer-reviewed articles.

  • Neil_Gibson

  • Neil Gibson, Ph.D.

    Neil W. Gibson, Ph.D. was most recently Senior Vice President of BioAtla, a private company focused on the discovery and development of conditionally active biological (CABs). Prior to that he was the Chief Scientific Officer of Regulus Therapeutics, where he was responsible for leading all research and development efforts at Regulus. Dr. Gibson has more than 25 years of drug development experience and has been involved in the successful discovery, development and commercialization of four approved oncology drugs (including temozolomide, sorafenib, erlotnib, and crizotinib). Dr. Gibson joined Regulus from the Oncology Research Unit at Pfizer, La Jolla, where he was the Chief Scientific Officer and Oncology Therapeutic Area head. Dr. Gibson also held leadership roles on Pfizer’s Oncology Business Unit leadership team and global leadership team of Pfizer’s Pharmatherapeutics Organization. Prior to his years at Pfizer, Dr. Gibson held positions at OSI Pharmaceuticals (OSIP), including Chief Scientific Officer, Senior Director of Cancer Discovery and Vice President of Research. Dr. Gibson’s industry experience has also included service as a Director for Cancer Research in the Department of Cancer and Osteoporosis for Bayer.

    Dr. Gibson has held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, Dr. Gibson has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Dr. Gibson earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.

  • C_Rader

  • Christoph Rader, Ph.D.

    Dr. Christoph Rader is an Associate Professor with Tenure in the Department of Immunology and Microbiology at The Scripps Research Institute in Jupiter, Florida (TSRI-FL). Dr. Rader joined TSRI-FL after 9 years as the Head of the Antibody Technology Section in the Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland. Prior to this position, Dr. Rader was Assistant Professor in the Department of Molecular Biology at The Scripps Research Institute in La Jolla, California (TSRI-CA) from 1999 to 2003. He was a postdoc in the laboratory of Dr. Carlos F. Barbas III at TSRI-CA from 1996 to 1999 after graduating with a Ph.D. in biochemistry and molecular biology from the University of Zurich in Zurich, Switzerland. Dr. Rader is a leading scientist in antibody drug and target discovery for cancer therapy. He has authored >100 journal articles and book chapters, is named inventor on >25 issued and pending patent applications, and lectures frequently. Antibodies developed in Dr. Rader’s NIH-funded laboratories at TSRI-CA, NIH, and TSRI-FL have been licensed to companies and translated to clinical trials. A particular focus of Dr. Rader’s TSRI-FL laboratory is devoted to antibody technologies at the interface of biology and chemistry, including the generation of site-specific antibody-drug conjugates and chemically programmed antibodies.

  • Morris Rosenberg, DSc.

    Dr. Rosenberg is widely regarded as an expert in the development, scale up and manufacturing of recombinant human therapeutics. He has over 28 years industry experience and was most recently employed as Executive Vice President of Development and Manufacturing at Seattle Genetics where he played a key role in the development of their antibody drug conjugate platform and the successful launch of Adcetris for Hodgkin Lymphoma.